Evommune EVMN
NYSE EVMN
$8.31 -0.05 (-0.54%)
As of: Sep 30, 2026 · 3:01 PM EDT

Evommune (EVMN) Net Income (2024 - 2026)

Updated

Evommune (EVMN) recorded Net Income of -$32.24 million in Q2 2026, compared with -$22.59 million a year earlier.

Analysis

Evommune (EVMN) Net Income (2024 - 2026) Analysis & Trends

On a TTM basis, Evommune's Net Income came in at -$94.65 million as of Jun 30, 2026; for FY2025, it was -$77.75 million.

  • Across earlier years, Net Income came in at -$66.77 million in FY2024.
  • The Q2 2026 figure is the lowest quarterly Net Income in data going back to Q3 2024.
  • Per Business Quant, the preceding three quarters came in at -$21.67 million (Q1 2026), -$28.27 million (Q4 2025) and -$12.47 million (Q3 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Johnson & Johnson 645.01 Bn 563.54 Bn 17.26 Bn 5.53 Bn
2 AbbVie 465.23 Bn 438.39 Bn 12.70 Bn 3.62 Bn
3 Merck 368.40 Bn 322.83 Bn 12.21 Bn -1.34 Bn
4 Novartis Ag 278.02 Bn 233.89 Bn 11.24 Bn 3.26 Bn
5 Astrazeneca 254.57 Bn 228.13 Bn 12.86 Bn 2.51 Bn
6 Amgen 229.02 Bn 184.42 Bn 7.24 Bn 2.38 Bn
7 Gilead Sciences 187.74 Bn 161.85 Bn 6.22 Bn -10.50 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -237.00 Mn
9 Vertex Pharmaceuticals 133.45 Bn 105.45 Bn 2.84 Bn 1.10 Bn
10 Evommune 302.59 Mn -334.93 Mn - -32.24 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -32.24 Mn
Mar 31, 2026 -21.67 Mn
Dec 31, 2025 -28.27 Mn
Sep 30, 2025 -12.47 Mn
Jun 30, 2025 -22.59 Mn
Mar 31, 2025 -14.42 Mn
Dec 31, 2024 -20.73 Mn
Sep 30, 2024 -15.90 Mn
API Access

Evommune Net Income API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=net-income&ticker=EVMN&period=max&api_key=YOUR_API_KEY